Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy ProfilingSabrina Weber, Ellen Heitzer, Dominic G. Rothwell et al.|Cancers|2020Cited by 69
Abstract CT130: Molecular-biological tumor profiling for drug treatment selection in patients with advanced and refractory carcinoma: A prospective, two-stage Phase II individualized cancer treatment studySamantha Perakis, Armin Gerger, Peter Ulz et al.|Cancer Research|2019Cited by 0
Abstract 4295: Early circulating tumor DNA dynamics as a real-time predictor of FOLFOX efficacy in advanced colorectal cancer patientsTina Moser, Michael R. Speicher, Julie Waldispuehl‐Geigl et al.|Cancer Research|2020Cited by 0
1938P Profiling of circulating tumour DNA for treatment selection in patients with advanced and refractory carcinoma: A prospective, two-stage phase II individualized cancer treatment trialArmin Gerger, Ellen Heitzer, Jakob M. Riedl et al.|Annals of Oncology|2020Cited by 0
Abstract CT130: Molecular-biological tumor profiling for drug treatment selection in patients with advanced and refractory carcinoma: A prospective, two-stage Phase II individualized cancer treatment studySamantha Perakis, Armin Gerger, Peter Ulz et al.|Clinical Trials|2019Cited by 0